Table 2 Univariate and multivariate Cox proportional hazard analyses for cancer-specific survival

Age, years (<60 vs ≥60)

0.69(0.31–1.51)

0.35

0.53(0.19–1.48)

0.23

Gender (male vs female)

0.58(0.26–1.29)

0.18

0.42(0.15–1.17)

0.098

Laterality (left vs right)

1.43(0.64–3.18)

0.38

1.29(0.45–3.70)

0.63

Clinical symptom(yes vs no)

3.14(1.25–7.90)

0.018

1.05(0.35–3.11)

0.93

1.72(0.61–4.86)

0.31

Tumor size, cm (<7 vs ≥7)

0.60(0.25–1.46)

0.26

0.64(0.22–1.90)

0.42

ECOG-PS (2–3 vs 0–1)

6.32(2.86–13.9)

0.000

1.22(0.30–4.98)

0.78

4.90(1.73–13.9)

0.003

2.43(0.89–8.67)

0.062

Histological type (clear vs others)

0.71(0.44–2.15)

0.24

0.72(0.24–2.11)

0.55

Tumor grade (G3–G4 vs G1–G2)

5.41(2.01–14.6)

0.001

2.44(0.74–8.05)

0.14

4.15(1.30–13.3)

0.016

4.18(1.43–12.9)

0.010

T stage (T3c–T4 vs T3a–T3b)

7.29(3.17–16.8)

0.000

4.17(0.85–20.3)

0.78

6.05(1.96–18.7)

0.002

3.74(0.77–11.2)

0.612

N stage (N1 vs N0 or Nx)

13.9(5.45–35.7)

0.000

5.44(1.50–19.7)

0.010

11.0(3.60–33.9)

0.000

6.74(1.39–32.7)

0.018

M stage (M1 vs M0)

16.0(6.34–40.4)

0.000

5.12(1.29–20.3)

0.020

-

-

Perinephric fat invasion (yes vs no)

3.99(1.76–9.05)

0.001

1.48(0.49–4.44)

0.48

3.01(1.09–8.31)

0.034

4.92(1.29–18.7)

0.019

Renal pelvis invasion (yes vs no)

1.15(0.42–3.10)

0.79

2.02(0.71–5.75)

0.19

Thrombus level (I–III vs 0)

1.68(0.76–3.68)

0.197

1.09(0.39–3.08)

0.87

Invasion of IVC wall (yes vs no)

6.16(2.62–14.5)

0.000

4.81(1.02–12.1)

0.048

5.10(1.39–18.8)

0.014

1.61(0.59–16.1)

0.073

Neoadjuvant-molecular-targeted therapy (yes vs no)

0.27(0.0–251.3)

0.52

-

-